^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Anyara (naptumomab estafenatox)

    i
    Other names: ABR-217620, TTS CD3, 5T4FabV18-SEA/E-120, NTX-352
    Associations

    News

    Trials
    Company:
    Active Biotech, NeoTX
    Drug class:
    T-cell stimulant, 5T4-targeted antibody-drug conjugate
    Related drugs:
    Associations

    News

    Trials
    8ms
    Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial Cancers (clinicaltrials.gov)
    P1, N=0, Withdrawn, Weill Medical College of Cornell University | N=30 --> 0 | Initiation date: Jun 2023 --> Nov 2023 | Not yet recruiting --> Withdrawn | Trial primary completion date: Aug 2024 --> Dec 2025
    Enrollment change • Trial initiation date • Trial withdrawal • Trial primary completion date • Combination therapy
    |
    Keytruda (pembrolizumab) • Gazyva (obinutuzumab) • Anyara (naptumomab estafenatox)
    10ms
    Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=60, Active, not recruiting, NeoTX Therapeutics Ltd. | Phase classification: P1b --> P1 | Trial completion date: Aug 2025 --> Oct 2026 | Trial primary completion date: May 2025 --> Oct 2026
    Phase classification • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • TPBG (Trophoblast Glycoprotein)
    |
    HER-2 negative • TPBG positive
    |
    Imfinzi (durvalumab) • Gazyva (obinutuzumab) • Anyara (naptumomab estafenatox)
    10ms
    NT-NAP-102-1: Naptumomab Estafenatox (NAP) in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC (clinicaltrials.gov)
    P2, N=38, Completed, NeoTX Therapeutics Ltd. | Active, not recruiting --> Completed | Phase classification: P2a --> P2 | Trial completion date: Jul 2024 --> Jan 2024
    Trial completion • Phase classification • Trial completion date
    |
    docetaxel • Gazyva (obinutuzumab) • Anyara (naptumomab estafenatox)
    1year
    Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1b, N=60, Active, not recruiting, NeoTX Therapeutics Ltd. | Trial completion date: Aug 2023 --> Aug 2025 | Trial primary completion date: May 2023 --> May 2025
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • TPBG (Trophoblast Glycoprotein)
    |
    HER-2 negative • TPBG positive
    |
    Imfinzi (durvalumab) • Gazyva (obinutuzumab) • Anyara (naptumomab estafenatox)
    over1year
    Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial Cancers (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Weill Medical College of Cornell University
    New P1 trial • Combination therapy
    |
    Keytruda (pembrolizumab) • Gazyva (obinutuzumab) • Anyara (naptumomab estafenatox)
    almost2years
    Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1b, N=60, Active, not recruiting, NeoTX Therapeutics Ltd. | Trial completion date: May 2023 --> Aug 2023
    Trial completion date • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • TPBG (Trophoblast Glycoprotein)
    |
    HER-2 negative • TPBG positive
    |
    Imfinzi (durvalumab) • Gazyva (obinutuzumab) • Anyara (naptumomab estafenatox)
    2years
    Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1b, N=60, Active, not recruiting, NeoTX Therapeutics Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • TPBG (Trophoblast Glycoprotein)
    |
    HER-2 negative • TPBG positive
    |
    Imfinzi (durvalumab) • Gazyva (obinutuzumab) • Anyara (naptumomab estafenatox)
    over2years
    NT-NAP-102-1: Naptumomab Estafenatox (NAP) in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC (clinicaltrials.gov)
    P2a, N=35, Recruiting, NeoTX Therapeutics Ltd. | Trial primary completion date: Jun 2023 --> Oct 2023
    Trial primary completion date • Combination therapy • Checkpoint inhibition
    |
    EGFR (Epidermal growth factor receptor)
    |
    docetaxel • Gazyva (obinutuzumab) • Anyara (naptumomab estafenatox)
    over2years
    Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1b, N=50, Recruiting, NeoTX Therapeutics Ltd. | Trial completion date: Jul 2022 --> Mar 2023 | Trial primary completion date: Apr 2022 --> Dec 2022
    Trial completion date • Trial primary completion date • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • TPBG (Trophoblast Glycoprotein)
    |
    HER-2 negative • TPBG positive
    |
    Imfinzi (durvalumab) • Gazyva (obinutuzumab) • Anyara (naptumomab estafenatox)
    3years
    Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1b, N=50, Recruiting, NeoTX Therapeutics Ltd. | Trial completion date: Feb 2022 --> Jul 2022 | Trial primary completion date: Nov 2021 --> Apr 2022
    Clinical • Trial completion date • Trial primary completion date • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • TPBG (Trophoblast Glycoprotein)
    |
    HER-2 negative • TPBG positive
    |
    Imfinzi (durvalumab) • Gazyva (obinutuzumab) • Anyara (naptumomab estafenatox)
    3years
    NT-NAP-102-1: Naptumomab Estafenatox (NAP) in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC (clinicaltrials.gov)
    P2a, N=35, Recruiting, NeoTX Therapeutics Ltd. | Not yet recruiting --> Recruiting
    Clinical • Enrollment open • Combination therapy • Checkpoint inhibition
    |
    EGFR (Epidermal growth factor receptor)
    |
    docetaxel • Gazyva (obinutuzumab) • Anyara (naptumomab estafenatox)
    over3years
    NT-NAP-102-1: Naptumomab Estafenatox (NAP) in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC (clinicaltrials.gov)
    P2a, N=35, Not yet recruiting, NeoTX Therapeutics Ltd.
    Clinical • New P2a trial • Combination therapy • Checkpoint inhibition
    |
    EGFR (Epidermal growth factor receptor)
    |
    docetaxel • Gazyva (obinutuzumab) • Anyara (naptumomab estafenatox)